Free Trial
NASDAQ:TYRA

Tyra Biosciences Q4 2024 Earnings Report

Tyra Biosciences logo
$10.18 -0.32 (-3.00%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tyra Biosciences EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Tyra Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tyra Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Tyra Biosciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Earnings Documents

Tyra Biosciences Earnings Headlines

Tyra Biosciences price target lowered to $28 from $29 at BofA
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Tyra Biosciences reports Q4 EPS (43c) vs. (53c) last year
See More Tyra Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email.

About Tyra Biosciences

Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

View Tyra Biosciences Profile

More Earnings Resources from MarketBeat